CagriSema vs Retatrutide: The Next-Gen GLP-1 Showdown

CagriSema vs Retatrutide: The Next-Gen GLP-1 Showdown

As of April 2026, two next-generation weight loss drugs remain in the pipeline — and neither is available to patients. CagriSema (Novo Nordisk) combines semaglutide with amylin for 22.7% weight loss in Phase 3 trials. Retatrutide (Eli Lilly) hits three receptors at once, showing up to 24.2% weight loss in Phase 2 — with Phase 3 results still pending.

CagriSema's NDA was filed in December 2025 and is under FDA review with no PDUFA date publicly disclosed. Retatrutide is still in Phase 3 trials. The timeline for both remains uncertain.

Meanwhile, CagriSema failed to match tirzepatide in a head-to-head trial, raising real questions about whether it offers anything beyond what Zepbound already delivers. And retatrutide's Phase 3 data — the data that will ultimately determine its real-world efficacy — has not been published.

Here's what the clinical data actually says, how these drugs compare to each other and to current options, and — most importantly — whether you should wait. Patients searching "CagriSema vs retatrutide which is better" or "best GLP-1 for weight loss without insurance" will find both questions answered below.

What is the next-gen GLP-1 landscape that CagriSema and retatrutide are entering?

Tirzepatide (Zepbound) currently leads the market with 20.9% weight loss at 72 weeks — CagriSema and retatrutide both aim to surpass it through different mechanisms. Neither is available yet, and retatrutide is further from approval than CagriSema.

The current generation of GLP-1 medications topped out with tirzepatide (Zepbound), which produces about 20.9% weight loss at 72 weeks. That was a genuine breakthrough. CagriSema and retatrutide represent two different strategies for going further — and a third competitor, survodutide (a dual GLP-1/glucagon agonist from Boehringer Ingelheim), is also advancing in this next-gen space.

CagriSema's approach: Stack two appetite-suppression mechanisms. Take the proven GLP-1 agonist semaglutide and add cagrilintide, an amylin analog that suppresses appetite through a separate brain pathway. Two drugs, one injection, more appetite suppression.

Retatrutide's approach: Build a single molecule that activates three receptors — GLP-1, GIP, and glucagon. The first two reduce appetite (like tirzepatide does). The third, glucagon, does something no current obesity drug does: it tells the body to burn more energy, particularly from fat stores.

These are fundamentally different strategies, and the early data suggests they may produce meaningfully different results — though we are still waiting for retatrutide's Phase 3 confirmation.

How do CagriSema and retatrutide compare directly?

CagriSema (GLP-1 + amylin) produced 22.7% weight loss in Phase 3 and has filed its NDA; retatrutide (GLP-1 + GIP + glucagon) showed up to 24.2% in Phase 2 but is still in Phase 3 trials. CagriSema is closer to approval; retatrutide may ultimately produce more weight loss if Phase 3 data holds. For patients asking "CagriSema vs retatrutide which is better," the honest answer is: we don't fully know yet.

Factor	CagriSema (Novo Nordisk)	Retatrutide (Eli Lilly)
Mechanism	GLP-1 + amylin (dual agonist)	GLP-1 + GIP + glucagon (triple agonist)
Components	Cagrilintide 2.4mg + semaglutide 2.4mg	Single molecule, 3 receptor targets
Weight loss	22.7% (REDEFINE-1, 68 weeks, Phase 3)	Up to 24.2% (Phase 2, 48 weeks) — Phase 3 pending
Patients losing ≥20%	~58% (Phase 3)	Data pending (Phase 3)
Administration	Weekly injection	Weekly injection
NDA status	Filed December 2025 — under review since December 2025 with no FDA decision	Still in Phase 3 (TRIUMPH program). NDA expected late 2027 or 2028
FDA decision	Unknown — no PDUFA date disclosed, significant delay	2028-2029 at earliest
Non-inferiority vs tirzepatide	MISSED — did not prove non-inferiority	Not yet tested against tirzepatide
Liver fat reduction	No specific Phase 3 data	80-90% (Phase 2) — Phase 3 pending
Cardiovascular outcomes data	Inherits semaglutide's SELECT trial	None yet
Expected pricing	$1,200-1,500/mo estimated	Unknown (Lilly typically competitive)
Key strength	Closer to market (if FDA acts); Novo Nordisk ecosystem	Potentially highest efficacy; liver fat reduction
Key weakness	Did not beat tirzepatide; FDA delay raises questions	Still in Phase 3; years from availability

Important context on the weight loss numbers: Retatrutide's 24.2% figure comes from Phase 2 data at 48 weeks. CagriSema's 22.7% comes from Phase 3 at 68 weeks. Comparing Phase 2 to Phase 3 data is inherently uncertain — Phase 3 results sometimes come in lower than Phase 2. We will not know retatrutide's true Phase 3 efficacy until the TRIUMPH program publishes results.

What does the clinical data on CagriSema show?

CagriSema produced 22.7% weight loss in REDEFINE-1 (68 weeks) — a clear upgrade over semaglutide alone — but failed to beat tirzepatide in the head-to-head REDEFINE-4 trial (22.2% vs 25.3%). That non-inferiority miss is the most important caveat for patients considering it.

How it works

CagriSema delivers two drugs in a single weekly injection:

1. Semaglutide 2.4mg — the same GLP-1 receptor agonist in Wegovy and Ozempic. Suppresses appetite, slows gastric emptying, improves blood sugar control. This is the most extensively studied obesity drug in history.

2. Cagrilintide 2.4mg — a long-acting amylin analog. Amylin is a hormone your pancreas releases alongside insulin after meals. It acts on brain regions that regulate satiety, fullness, and food reward through pathways that are complementary to but distinct from GLP-1.

The theory: two different appetite-suppression systems working simultaneously produce more weight loss than either alone. Researchers describe this as a synergistic effect — the combination outperforms what you'd predict from adding the individual effects together.

What CagriSema does not do: It does not increase energy expenditure. Both components reduce caloric intake through appetite and satiety mechanisms. All weight loss is driven from the intake side of the equation.

Clinical trial data (REDEFINE program)

Trial	Population	Duration	Mean Weight Loss	Key Finding
REDEFINE-1	Obesity (no diabetes)	68 weeks	22.7%	Primary Phase 3 obesity trial
REDEFINE-2	Type 2 diabetes	68 weeks	15.7%	Lower efficacy in T2D (typical for GLP-1 class)
REDEFINE-4	CagriSema vs tirzepatide	72 weeks	22.2% vs 25.3%	Did not meet non-inferiority

The 22.7% result from REDEFINE-1 is strong on its own — it substantially outperforms semaglutide alone (14.9% in STEP-1). But REDEFINE-4 is the trial that matters most for understanding where CagriSema fits.

Regulatory status: NDA under review

CagriSema's NDA was filed in December 2025. As of April 2026, the FDA has not yet issued a decision, which is not unexpected given the NDA was filed just three months ago. No PDUFA target date has been publicly disclosed, and Novo Nordisk has not provided clear guidance on when a decision might come.

The reasons for the delay are not publicly confirmed. Possibilities include additional data requests, manufacturing inspections, or the complexity of reviewing a combination product with two active ingredients. Whatever the cause, the prolonged review period adds uncertainty for patients and providers who had expected a decision by late 2026.

It is important to acknowledge what we do not know: the delay could reflect routine regulatory complexity, or it could signal substantive concerns. We will update this page when more information becomes available.

Side effects

CagriSema's tolerability profile is broadly similar to high-dose semaglutide:

• Nausea: ~40-45% (mostly during dose escalation)
• Diarrhea: ~20-25%
• Vomiting: ~15-20%
• Constipation: ~10-15%
• Discontinuation due to GI side effects: ~5-7%

The amylin component adds some additional nausea but does not dramatically change the tolerability picture compared to semaglutide alone. Most GI symptoms peak during dose titration and settle within 2-4 weeks at each dose level.

Cardiovascular evidence

CagriSema inherits semaglutide's cardiovascular data from the SELECT trial — a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients with established cardiovascular disease. This is inherited, not directly studied with CagriSema, but it provides a level of cardiovascular reassurance that retatrutide currently lacks.

What does the clinical data on retatrutide show?

Retatrutide's Phase 2 data showed up to 24.2% weight loss at 48 weeks and an extraordinary 80-90% liver fat reduction — results driven by its unique glucagon receptor activation. Phase 3 data from the TRIUMPH program is still pending, so these numbers remain unconfirmed at scale.

How it works

Retatrutide is a single molecule engineered to activate three different receptors simultaneously:

1. GLP-1 receptor — appetite suppression, blood sugar control. The same target as semaglutide and every other GLP-1 medication.

2. GIP receptor — enhances fat metabolism and insulin sensitivity. The same additional target as tirzepatide (Zepbound/Mounjaro). This is what makes tirzepatide more effective than semaglutide alone.

3. Glucagon receptor — this is the breakthrough component. Glucagon tells the body to burn more energy, particularly from fat stores, and drives the liver to break down stored fat.

The glucagon receptor is what makes retatrutide fundamentally different. Every other GLP-1 medication — approved or investigational — works primarily by making you eat less. Retatrutide makes you eat less and burn more. It attacks obesity from both sides of the energy balance equation.

This dual-sided mechanism likely explains two standout results from Phase 2: the magnitude of weight loss (up to 24.2%) and the dramatic 80-90% liver fat reduction. Whether these results hold up in the larger Phase 3 TRIUMPH program remains to be seen.

Clinical trial data (TRIUMPH program)

Trial	Phase	Population	Duration	Mean Weight Loss	Key Finding
Phase 2	Phase 2	Obesity (no diabetes)	48 weeks	Up to 24.2% (12mg)	Dose-dependent; weight still declining at 48 weeks
TRIUMPH program	Phase 3	Multiple populations	Ongoing	Data pending	Results expected but not yet published
TRANSCEND-T2D-1	Phase 3	Type 2 diabetes	Ongoing	Data pending

An important note on the weight loss numbers: the 24.2% figure comes from Phase 2. Phase 3 trials are larger and more representative of real-world patients, and results sometimes differ from Phase 2. Until the TRIUMPH Phase 3 data is published, we should treat the 24.2% number as promising but unconfirmed. The true Phase 3 efficacy could be higher, lower, or similar.

Side effects

Retatrutide's GI side effect profile from Phase 2 is broadly consistent with the GLP-1 class:

• Nausea: ~40-50% (during dose escalation)
• Diarrhea: ~20-30%
• Vomiting: ~15-25%
• Constipation: ~10-15%
• Discontinuation due to GI side effects: ~6-10%

The slightly higher ranges compared to CagriSema may reflect the glucagon component, but rates remain manageable based on Phase 2 data. The larger safety question — and the one the FDA will focus on — is whether chronic glucagon receptor activation has long-term effects that shorter trials haven't captured. This is a novel mechanism at this scale, and the regulatory bar for safety data may be higher than for drugs using only established receptor targets. The safety profile is less established than CagriSema's, given that we are still awaiting large-scale Phase 3 safety data.

Liver fat reduction: the standout benefit

Phase 2 data showed retatrutide produces 80-90% liver fat reduction — a result that dwarfs everything else in the GLP-1 class:

Drug	Liver Fat Reduction
Retatrutide	80-90% (Phase 2 — Phase 3 pending)
Semaglutide	~62.9% MASH resolution (ESSENCE trial)
Tirzepatide	~30-40% estimated
CagriSema	No specific published data

For patients with non-alcoholic fatty liver disease (NAFLD/NASH/MASH), this Phase 2 data is significant. The glucagon component directly promotes hepatic fat oxidation — the liver burning its own stored fat — which is why the effect is so pronounced. Phase 3 confirmation is still needed, but the mechanism and early data are compelling.

No cardiovascular outcomes data

Retatrutide has no cardiovascular outcomes trial data. This is a meaningful gap. Semaglutide's SELECT trial and tirzepatide's ongoing SURPASS-CVOT program provide cardiovascular reassurance that retatrutide currently cannot match. For patients with established heart disease, this absence matters.

Why does the CagriSema non-inferiority failure matter?

CagriSema lost to tirzepatide in REDEFINE-4 (22.2% vs 25.3%), failing to prove it was even comparably effective. This directly limits CagriSema's positioning: it is a meaningful upgrade over Wegovy but not a step beyond Zepbound, which is already available.

The REDEFINE-4 trial — CagriSema vs tirzepatide — is the most important piece of data in this entire discussion, and it deserves clear explanation.

What happened

Novo Nordisk designed REDEFINE-4 to prove that CagriSema was "non-inferior" to tirzepatide — industry language for "at least as good." The trial ran 72 weeks. Results:

• CagriSema: 22.2% weight loss
• Tirzepatide: 25.3% weight loss
• Non-inferiority margin: Not met

CagriSema produced 3.1 percentage points less weight loss than tirzepatide, and the statistical analysis could not rule out a clinically meaningful difference. In plain terms: CagriSema is probably not as effective as tirzepatide for weight loss.

Why this matters

Tirzepatide is already available as Zepbound. If CagriSema cannot match Zepbound's efficacy, the value proposition narrows considerably:

• CagriSema vs Wegovy: Clear upgrade. 22.7% vs 14.9%. Patients on semaglutide who want more efficacy have a reason to consider CagriSema.
• CagriSema vs Zepbound: Not clearly better, and possibly worse. Patients already on tirzepatide have little reason to switch.
• CagriSema vs retatrutide: Potentially less effective based on cross-trial comparison with Phase 2 data, but Phase 3 confirmation is pending.

What this does NOT mean

The non-inferiority miss does not make CagriSema a bad drug. 22.7% weight loss is excellent. Many patients will respond better to CagriSema than to tirzepatide — individual variation is real. And CagriSema's semaglutide component carries cardiovascular outcomes data that tirzepatide does not yet have.

But the positioning is clear: CagriSema is a meaningful upgrade over Wegovy. It is not a leap beyond Zepbound.

How do CagriSema and retatrutide compare to currently available medications?

Against tirzepatide (Zepbound), CagriSema lost in a head-to-head trial. Retatrutide's Phase 2 data suggests it may outperform tirzepatide, but Phase 3 confirmation is required. Both pipeline drugs are more expensive and less available than current options.

CagriSema and retatrutide vs tirzepatide (Zepbound)

	Zepbound	CagriSema	Retatrutide
Weight loss	20.9% (72 wk)	22.7% (68 wk)	Up to 24.2% (48 wk, Phase 2)
Available now?	Yes	No (FDA review ongoing — under review since December 2025)	No (Phase 3 ongoing)
Mechanism	GLP-1 + GIP	GLP-1 + amylin	GLP-1 + GIP + glucagon
Cost	$299-449/mo (LillyDirect)	TBD ($1,200-1,500 est.)	TBD
Head-to-head result	—	Beat CagriSema (REDEFINE-4)	Not tested

Zepbound remains the efficacy leader among available medications. CagriSema offers a modest improvement over Wegovy but did not prove non-inferior to Zepbound. Retatrutide, if Phase 3 data confirms the Phase 2 results, could represent a genuine leap — but it is not available and the data is not yet confirmed.

CagriSema and retatrutide vs semaglutide (Wegovy)

	Wegovy (injectable)	Oral Wegovy	CagriSema	Retatrutide
Weight loss	14.9% (68 wk)	16.6% (68 wk)	22.7% (68 wk)	Up to 24.2% (48 wk, Phase 2)
Available now?	Yes	Yes	No	No
CV outcomes data	SELECT trial	Inherited	Inherited	None

CagriSema is a clear upgrade over Wegovy. If you're on semaglutide and have plateaued, CagriSema adds the amylin pathway for an additional ~8 percentage points of weight loss. This remains CagriSema's strongest use case — whenever the FDA reaches a decision.

CagriSema and retatrutide vs orforglipron

	Orforglipron	CagriSema	Retatrutide
Weight loss	~12.4% (48 wk)	22.7% (68 wk)	Up to 24.2% (48 wk, Phase 2)
Route	Daily pill	Weekly injection	Weekly injection
Cost	$149/mo	TBD ($1,200-1,500 est.)	TBD
Available now?	Yes	No	No

Orforglipron produces less weight loss but offers unmatched convenience (daily pill, no food restrictions) at $149/month. For patients who prioritize convenience and cost, orforglipron may remain the right choice even after CagriSema and retatrutide eventually launch.

The survodutide factor

Survodutide (Boehringer Ingelheim) is another next-gen competitor worth watching. It is a dual GLP-1/glucagon receptor agonist — sharing the glucagon component with retatrutide but without the GIP receptor activity. It produced up to 18.7% weight loss in Phase 2 and is advancing through its own Phase 3 program. Survodutide adds another variable to this next-gen landscape, though its efficacy appears to fall between current options and retatrutide's Phase 2 results.

Should you wait for CagriSema or retatrutide instead of starting treatment now?

No — for most patients, starting on an available medication now is the right call. Neither drug is accessible, both timelines are uncertain, and you can switch later if a next-gen option offers meaningful improvement for your situation.

This is the practical question, and as of April 2026, the answer is clear: no, start treatment now.

The case against waiting

1. Neither drug is available, and both timelines are uncertain. CagriSema's NDA was filed December 2025 and is under review; FDA decisions typically take 6-12 months. Retatrutide is still in Phase 3 trials. Starting treatment now means you benefit immediately rather than waiting for an uncertain future approval.

2. Every month of untreated obesity carries real costs. Metabolic damage, cardiovascular risk, joint stress, sleep disruption, and quality of life all worsen with time. Starting treatment today provides immediate benefit. Waiting for a drug with an uncertain timeline means accepting those costs for uncertain future gains.

3. CagriSema may not be worth waiting for specifically. It didn't beat tirzepatide, which is available right now. If you can access Zepbound, you may already be getting comparable or better results than CagriSema will offer.

4. Retatrutide's Phase 3 data is still pending. The 24.2% Phase 2 result is promising, but Phase 3 results sometimes come in differently. We cannot confirm retatrutide's real-world efficacy until the TRIUMPH data is published. An NDA filing is expected late 2027 or 2028, with an FDA decision in 2028-2029 at the earliest.

5. You can switch later. Starting on semaglutide, tirzepatide, or orforglipron does not lock you in. When new options become available, you and your provider can evaluate whether switching makes clinical sense based on your actual response.

6. Approval is not guaranteed. Both drugs have positive data, but FDA decisions are inherently uncertain. CagriSema's prolonged review raises questions. Retatrutide's novel glucagon mechanism could face additional safety scrutiny. The REDEFINE-4 non-inferiority miss could complicate CagriSema's labeling.

The rare exceptions

There are narrow situations where waiting might be reasonable:

• You have NASH/MASH and current treatments aren't working. Retatrutide's Phase 2 liver fat data is extraordinary, and no available drug comes close. If you're managing liver disease and can tolerate the wait, discuss this with your hepatologist — but do not stop other treatments in the meantime. Be aware that retatrutide is likely 1.5-2+ years from availability.

• You're already doing well on current treatment and curious about switching. There is no urgency. Continue your current medication and reassess when new options launch.

• You've tried and failed multiple GLP-1 medications. If semaglutide and tirzepatide haven't worked, CagriSema's different mechanism (amylin) could theoretically provide a response. This is speculative but worth discussing with your provider if and when CagriSema receives approval.

What is the right decision based on your patient situation?

The right choice depends on where you are in treatment. Patients not yet on any medication should start now with available options. Patients already on tirzepatide have no clear reason to wait for CagriSema. Patients with NASH/MASH have the strongest rationale to keep retatrutide on their radar.

"I'm not currently on any weight loss medication."

Start treatment now. Talk to your provider about tirzepatide (Zepbound) or semaglutide (Wegovy) based on your budget and insurance. Orforglipron is expected around April 10 (PDUFA date) at $149/month — an affordable option to consider once available. Do not wait for CagriSema or retatrutide. Neither is available, and both timelines remain uncertain. You can switch later if a next-gen option provides meaningful improvement.

"I'm on semaglutide (Wegovy/Ozempic) and it's working."

Continue. If and when CagriSema receives FDA approval, discuss with your provider whether the additional amylin mechanism could help you lose more weight. CagriSema is a natural upgrade path for semaglutide patients. No rush — keep benefiting from your current treatment.

"I'm on semaglutide and I've plateaued."

Try tirzepatide (Zepbound) now. It's available today and produces more weight loss than semaglutide. CagriSema didn't beat tirzepatide in REDEFINE-4, so switching to Zepbound is the stronger evidence-based move. If tirzepatide also doesn't work, CagriSema or eventually retatrutide may offer different pathways.

"I'm on tirzepatide (Zepbound) and doing well."

No reason to switch to CagriSema. CagriSema did not prove non-inferior to tirzepatide. Continue your current treatment. When retatrutide eventually launches, its potentially higher efficacy and different mechanism may be worth discussing — but that remains 1.5-2+ years away and Phase 3 data is still pending.

"I'm on tirzepatide and I've plateaued."

CagriSema's different mechanism (amylin vs GIP) could theoretically help, but there is no data showing CagriSema works in tirzepatide non-responders. Discuss with your provider if CagriSema becomes available. Retatrutide's triple mechanism is the most promising option for patients who haven't responded to dual agonists, but the wait is long and Phase 3 data is unconfirmed.

"I have fatty liver disease (NASH/MASH)."

Start treatment now with tirzepatide or semaglutide. Both reduce liver fat meaningfully. Keep retatrutide on your radar — its Phase 2 data showing 80-90% liver fat reduction is in a different league, though Phase 3 confirmation is needed. Discuss with your hepatologist whether your treatment plan should factor in retatrutide's timeline.

"Cost is my primary concern."

Orforglipron at $149/month is the clear winner among available options. CagriSema and retatrutide will likely launch at $1,000+/month before self-pay programs. Even with manufacturer discounts, next-gen drugs will almost certainly cost more than orforglipron. Start affordable treatment now.

"I want the absolute best weight loss possible and I can wait."

Start treatment now and plan to switch. Begin with tirzepatide for the best currently available results (20.9%). When retatrutide eventually launches — assuming Phase 3 confirms the Phase 2 data — its efficacy could represent a genuine step up. But waiting idle for 1.5-2+ years costs you the metabolic benefits of current treatment.

Frequently Asked Questions

Which produces more weight loss, CagriSema or retatrutide?

Based on available data, retatrutide may have an edge, but certainty is limited. Retatrutide produced up to 24.2% mean weight loss in Phase 2 (48 weeks). CagriSema produced 22.7% in Phase 3 REDEFINE-1 (68 weeks). However, comparing Phase 2 data to Phase 3 data has significant limitations — Phase 3 results sometimes differ. We will have a clearer answer when the TRIUMPH Phase 3 data is published.

Did CagriSema beat tirzepatide?

No. In the REDEFINE-4 head-to-head trial, CagriSema (22.2% weight loss) failed to meet non-inferiority against tirzepatide (25.3%). This means CagriSema is probably not as effective as tirzepatide — and tirzepatide is already available as Zepbound.

When will CagriSema be available?

That remains unclear. CagriSema's NDA was filed in December 2025, and as of April 2026, the FDA has not yet issued a decision. No PDUFA target date has been publicly disclosed. We will update this page when more information becomes available.

When will retatrutide be available?

Retatrutide is still in Phase 3 trials (the TRIUMPH program). An NDA filing is expected late 2027 or 2028. Even if filing proceeds on schedule, an FDA decision would come in 2028-2029 at the earliest. Manufacturing scale-up for a novel triple agonist adds additional complexity.

Can I switch from my current GLP-1 to CagriSema or retatrutide when they launch?

Yes, with clinical supervision. Starting on one GLP-1 medication does not prevent switching to another. Your provider will manage the transition, which typically involves dose re-titration on the new medication. There is no reason to delay treatment now.

Is retatrutide better for fatty liver disease?

Based on Phase 2 data, potentially yes. Retatrutide's glucagon receptor activation produced 80-90% liver fat reduction — far exceeding semaglutide (~62.9% MASH resolution) and tirzepatide (~30-40%). However, this is Phase 2 data and Phase 3 confirmation is needed. For patients with NAFLD/NASH/MASH, retatrutide is the most promising pipeline option, but its availability is still years away.

Will CagriSema or retatrutide be covered by insurance?

Unknown until after FDA approval. Based on patterns with Wegovy and Zepbound, expect limited coverage initially with gradual expansion over 12-under review since December 2025. Manufacturer savings programs will likely be available at launch. Neither will be cheap at launch — plan for $1,000+/month at list price.

Are the side effects worse than current GLP-1 medications?

Both drugs produce GI side effects (nausea, diarrhea, vomiting) at rates comparable to current GLP-1 medications. Most symptoms occur during dose escalation and improve with time. Retatrutide's safety profile is less established than CagriSema's, given that large-scale Phase 3 safety data has not been published. Its novel glucagon component may produce slightly higher GI rates, but Phase 2 discontinuation rates remained in the manageable 5-10% range.

Should I stop my current medication to prepare for switching?

No. Continue your current treatment until your provider advises otherwise. Stopping treatment leads to weight regain. When a new option becomes available, your provider will manage the transition directly.

What about survodutide?

Survodutide (Boehringer Ingelheim) is a dual GLP-1/glucagon receptor agonist advancing through Phase 3 trials. It shares the glucagon component with retatrutide but does not target the GIP receptor. Phase 2 data showed up to 18.7% weight loss. It is another next-gen option to watch, though its efficacy appears lower than both CagriSema and retatrutide based on available data.

Related Resources

• Semaglutide vs Tirzepatide — How the two leading GLP-1 medications compare
• Zepbound vs Wegovy — Head-to-head comparison of current top options
• Orforglipron vs Tirzepatide — Pill vs injection from Eli Lilly
• Orforglipron vs Oral Wegovy — The oral GLP-1 pills compared (orforglipron pending FDA approval)
• GLP-1 Oral Pills vs Injections — Should you take a pill or injection?
• Best GLP-1 Weight Loss Programs 2026 — All providers ranked